AU2019211352A1 - Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon - Google Patents

Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon Download PDF

Info

Publication number
AU2019211352A1
AU2019211352A1 AU2019211352A AU2019211352A AU2019211352A1 AU 2019211352 A1 AU2019211352 A1 AU 2019211352A1 AU 2019211352 A AU2019211352 A AU 2019211352A AU 2019211352 A AU2019211352 A AU 2019211352A AU 2019211352 A1 AU2019211352 A1 AU 2019211352A1
Authority
AU
Australia
Prior art keywords
glucagon
analog
glucagon analog
hypoglycemia
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019211352A
Other languages
English (en)
Inventor
Brett Newswanger
Mary-Elizabeth PATTI
Steven J. Prestrelski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Xeris Pharmaceuticals Inc
Original Assignee
Joslin Diabetes Center Inc
Xeris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, Xeris Pharmaceuticals Inc filed Critical Joslin Diabetes Center Inc
Publication of AU2019211352A1 publication Critical patent/AU2019211352A1/en
Assigned to JOSLIN DIABETES CENTER, INC., XERIS PHARMACEUTICALS, INC. reassignment JOSLIN DIABETES CENTER, INC. Amend patent request/document other than specification (104) Assignors: JOSLIN DIABETES CENTER, XERIS PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019211352A 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon Abandoned AU2019211352A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620861P 2018-01-23 2018-01-23
US62/620,861 2018-01-23
PCT/US2019/014815 WO2019147718A1 (en) 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon

Publications (1)

Publication Number Publication Date
AU2019211352A1 true AU2019211352A1 (en) 2020-07-30

Family

ID=65352189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019211352A Abandoned AU2019211352A1 (en) 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon

Country Status (9)

Country Link
US (1) US20210030847A1 (https=)
EP (1) EP3743097A1 (https=)
JP (1) JP7444786B2 (https=)
KR (1) KR20200134213A (https=)
CN (1) CN111936159A (https=)
AU (1) AU2019211352A1 (https=)
BR (1) BR112020014719A2 (https=)
MX (1) MX2020007768A (https=)
WO (1) WO2019147718A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026899A1 (en) * 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
US12569203B2 (en) * 2021-01-22 2026-03-10 Cilag Gmbh International Bariatric surgery post-surgical monitoring
US12527515B2 (en) 2021-01-22 2026-01-20 Cilag Gmbh International Colorectal surgery post-surgical monitoring
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
AU2013295035B2 (en) * 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
DK3102184T3 (da) 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc Stabile formuleringer af peptider og fremgangsmåder til fremstilling
MY185334A (en) * 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
AU2016267052B2 (en) * 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
WO2016196976A1 (en) * 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AU2016304588A1 (en) * 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia

Also Published As

Publication number Publication date
JP2021511386A (ja) 2021-05-06
BR112020014719A2 (pt) 2020-12-08
MX2020007768A (es) 2020-11-12
WO2019147718A8 (en) 2020-08-06
EP3743097A1 (en) 2020-12-02
KR20200134213A (ko) 2020-12-01
WO2019147718A1 (en) 2019-08-01
US20210030847A1 (en) 2021-02-04
CN111936159A (zh) 2020-11-13
JP7444786B2 (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
JP7444786B2 (ja) 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
US11957736B2 (en) Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
US12514907B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
US20240238381A1 (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
US11590205B2 (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: JOSLIN DIABETES CENTER, INC.

Free format text: FORMER NAME(S): XERIS PHARMACEUTICALS, INC.; JOSLIN DIABETES CENTER

Owner name: XERIS PHARMACEUTICALS, INC.

Free format text: FORMER NAME(S): XERIS PHARMACEUTICALS, INC.; JOSLIN DIABETES CENTER

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 23 JAN 2023 TO 23 SEP 2023 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE CONTINUATION FEE HAS BEEN EXTENDED TO 23 SEP 2023

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application